These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 25165123)

  • 41. Estimated susceptibility of Canadian meningococcal B isolates to a meningococcal serogroup B vaccine (MenB-FHbp).
    Bettinger JA; Liberator P; Halperin SA; Vaudry W; Sadarangani M; Hao L; Lambert N; Jansen KU; Anderson AS; Tsang R;
    Vaccine; 2020 Feb; 38(8):2026-2033. PubMed ID: 31983586
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Neisseria meningitidis porA, fetA and fHbp gene distribution in Western Australia 2000 to 2011.
    Boan P; Metasan N; Tempone S; Harnett G; Speers DJ; Keil AD
    BMC Infect Dis; 2014 Dec; 14():686. PubMed ID: 25495685
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Diversity of meningococci associated with invasive meningococcal disease in the Republic of Ireland over a 19 year period, 1996-2015.
    Bennett DE; Meyler KL; Cafferkey MT; Cunney RJ
    PLoS One; 2020; 15(2):e0228629. PubMed ID: 32053601
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Diversity of Canadian meningococcal serogroup B isolates and estimated coverage by an investigational meningococcal serogroup B vaccine (4CMenB).
    Bettinger JA; Scheifele DW; Halperin SA; Vaudry W; Findlow J; Borrow R; Medini D; Tsang R;
    Vaccine; 2013 Dec; 32(1):124-30. PubMed ID: 23588089
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Predicted Strain Coverage of a New Meningococcal Multicomponent Vaccine (4CMenB) in Spain: Analysis of the Differences with Other European Countries.
    Abad R; Medina V; Stella M; Boccadifuoco G; Comanducci M; Bambini S; Muzzi A; Vázquez JA
    PLoS One; 2016; 11(3):e0150721. PubMed ID: 26950303
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Molecular characteristics of Neisseria meningitidis carriage strains in university students in Lithuania.
    Ivaškevičienė I; Silickaitė J; Mačionienė A; Ivaškevičius R; Bulavaitė A; Gėgžna V; Kiverytė S; Paškevič B; Žvirblienė A; Plečkaitytė M
    BMC Microbiol; 2023 Nov; 23(1):352. PubMed ID: 37978423
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Characterization of invasive Neisseria meningitidis from Atlantic Canada, 2009 to 2013: With special reference to the nonpolysaccharide vaccine targets (PorA, factor H binding protein, Neisseria heparin-binding antigen and Neisseria adhesin A).
    Tsang RS; Law DK; Gad RR; Mailman T; German G; Needle R
    Can J Infect Dis Med Microbiol; 2015; 26(6):299-304. PubMed ID: 26744586
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Distribution of factor H binding protein beyond serogroup B: variation among five serogroups of invasive Neisseria meningitidis in South Africa.
    Mothibeli KM; du Plessis M; von Gottberg A; Murphy E; Hoiseth SK; Zlotnick G; Klugman KP
    Vaccine; 2011 Mar; 29(11):2187-92. PubMed ID: 21144918
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Predicted coverage by 4CMenB vaccine against invasive meningococcal disease cases in the Netherlands.
    Freudenburg-de Graaf W; Knol MJ; van der Ende A
    Vaccine; 2020 Nov; 38(49):7850-7857. PubMed ID: 33097311
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Temporal Changes in BEXSERO® Antigen Sequence Type Associated with Genetic Lineages of Neisseria meningitidis over a 15-Year Period in Western Australia.
    Mowlaboccus S; Perkins TT; Smith H; Sloots T; Tozer S; Prempeh LJ; Tay CY; Peters F; Speers D; Keil AD; Kahler CM
    PLoS One; 2016; 11(6):e0158315. PubMed ID: 27355628
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Meningococcal B vaccine antigen FHbp variants among disease-causing Neisseria meningitidis B isolates, Italy, 2014-2017.
    Carannante A; Fazio C; Neri A; Lista F; Fillo S; Ciammaruconi A; Vacca P; Stefanelli P
    PLoS One; 2020; 15(11):e0241793. PubMed ID: 33176334
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Characterization of fHbp, nhba (gna2132), nadA, porA, sequence type (ST), and genomic presence of IS1301 in group B meningococcal ST269 clonal complex isolates from England and Wales.
    Lucidarme J; Comanducci M; Findlow J; Gray SJ; Kaczmarski EB; Guiver M; Kugelberg E; Vallely PJ; Oster P; Pizza M; Bambini S; Muzzi A; Tang CM; Borrow R
    J Clin Microbiol; 2009 Nov; 47(11):3577-85. PubMed ID: 19759227
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Phase Variation of NadA in Invasive Neisseria meningitidis Isolates Impacts on Coverage Estimates for 4C-MenB, a MenB Vaccine.
    Green LR; Lucidarme J; Dave N; Chan H; Clark S; Borrow R; Bayliss CD
    J Clin Microbiol; 2018 Sep; 56(9):. PubMed ID: 29950334
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Molecular characteristics of serogroup B
    Zhu BQ; Gao WY; Xu L; Gao Y; Shao ZJ
    Zhonghua Yu Fang Yi Xue Za Zhi; 2019 Feb; 53(2):153-158. PubMed ID: 30744288
    [No Abstract]   [Full Text] [Related]  

  • 55. Variability of genes encoding surface proteins used as vaccine antigens in meningococcal endemic and epidemic strain panels from Norway.
    Holst J; Comanducci M; Bambini S; Muzzi A; Comandi S; Oksnes J; DeTora L; Pizza M; Rappuoli R; Caugant DA
    Vaccine; 2014 May; 32(23):2722-31. PubMed ID: 24631075
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Distribution of Bexsero® Antigen Sequence Types (BASTs) in invasive meningococcal disease isolates: Implications for immunisation.
    Brehony C; Rodrigues CMC; Borrow R; Smith A; Cunney R; Moxon ER; Maiden MCJ
    Vaccine; 2016 Sep; 34(39):4690-4697. PubMed ID: 27521232
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Invasive serogroup B meningococci in England following three years of 4CMenB vaccination - First real-world data.
    Lucidarme J; Bai X; Lekshmi A; Clark SA; Willerton L; Ribeiro S; Campbell H; Serino L; De Paola R; Holland A; Louth J; Ramsay ME; Ladhani SN; Borrow R
    J Infect; 2022 Feb; 84(2):136-144. PubMed ID: 34838814
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Whole genome sequence analysis of Neisseria meningitidis strains circulating in Kazakhstan, 2017-2018.
    Shevtsov A; Aushakhmetova Z; Amirgazin A; Khegay O; Kamalova D; Sanakulova B; Abdaliyev A; Bayesheva D; Seidullayeva A; Ramankulov Y; Shustov A; Vergnaud G
    PLoS One; 2022; 17(12):e0279536. PubMed ID: 36576937
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Temporal variations in the serogroup distribution of invasive meningococcal disease in Quebec, Canada, due to emerging unique clade of serogroup Y strain belonging to the Sequence Type-23 clonal complex.
    Tsang RSW; Deceuninck G; Meilleur C; Zhou J; Lefebvre B; De Wals P
    J Infect; 2024 Jun; 88(6):106163. PubMed ID: 38670267
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Potential benefits of using a multicomponent vaccine for prevention of serogroup B meningococcal disease.
    Watson PS; Novy PL; Friedland LR
    Int J Infect Dis; 2019 Aug; 85():22-27. PubMed ID: 31102824
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.